

BrainCool AB (publ): BrainCool introduces MiniChill in Japan, the next generation RhinoChill technology for selective brain cooling

BrainCool is at the forefront of a new clinical development in Japan, with the latest generation of RhinoChill; MiniChill

The company has committed to provide products (with limited revenue of EUR 6,000) for an animal-based clinical trial/study, focusing on selective brain cooling using the updated RhinoChill technology. The clinical trial will be initiated at Nagoya University, at the Department of Emergency and Critical Care, with Dr. Mitsuaki Nishikimi as trial leader. Funding for the trial has been made possible through support from the ZOLL Foundation.

CEO Martin Waleij comments;

"RhinoChill, one of BrainCool's products, is the only approved product on the market that enables rapid brain cooling, both in and out of hospital.

RhinoChill does not affect patient management during resuscitation. Its high capacity guarantees a safe and efficient brain cooling process. By seamlessly integrating with resuscitation methods, RhinoChill, is a valuable asset in critical situations, offering unmatched performance and reliability."

In this study, MiniChill, the new generation RhinoChill, will be used. This innovative product was developed under the COOLHEAD project, which received an EU grant from Eurostars in 2019.

MiniChill represents significant progress and reduces the weight of today's product from 13 kg to only 5 kg. The improvement is a direct response to valuable feedback from the PRINCESS study, in which the ambulance service and EMS highlighted the size and weight as a limiting factor during emergency situations. BrainCool welcomed this feedback and created the next generation RhinoChill (MiniChill), now three times lighter, making it easier to adapt to different situations and easier to transport.

Design and functionality have mainly been retained. Some adjustments have been made to the electronic components and the alarm, to match the appropriate medical device standards.

The main objective of the Japanese study is to collect crucial data for selective brain cooling in a 'cardiac arrest model'.

The process of selective brain cooling involves targeting specific brain regions to protect them from damage during a cardiac arrest. This is achieved by inducing rapid brain cooling while keeping the body warm using an endovascular catheter.

The study results could be a game changer and lead to major medical advances, especially with regard to neuroprotection in the intensive care for heart disease.

Scientific Manager Mohammad Fazel comments;

"If the results are positive, it will support the market approval process for MiniChill in medical practice in Japan. Furthermore, the study will validate the effectiveness of the new RhinoChill technology, strengthening confidence among clinicians and potential users."

Contacts**For more information**

Martin Waleij - CEO

+46 - 733 -93 70 76

E-mail: martin.waleij@braincool.se

About Us

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Oncology.

BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named "BRAIN".

Eminova Fondkommission AB is the company's Certified Adviser.

Attachments

[BrainCool AB \(publ\): BrainCool introduces MiniChill in Japan, the next generation RhinoChill technology for selective brain cooling](#)